RT Journal Article
SR Electronic
T1 Evidence that extracellular HSPB1 contributes to inflammation in alcohol-associated hepatitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.06.24313193
DO 10.1101/2024.09.06.24313193
A1 Overstreet, Anne-Marie C
A1 Burge, McKenzie
A1 Bellar, Annette
A1 McMullen, Megan
A1 Czarnecki, Douglas
A1 Huang, Emily
A1 Pathak, Vai
A1 Finney, Chelsea
A1 Vij, Raveena
A1 Dasarathy, Srinivasan
A1 Dasarathy, Jaividhya
A1 Streem, David
A1 Welch, Nicole
A1 Rotroff, Daniel
A1 Schmitt, Adam M
A1 Nagy, Laura E
A1 Messer, Jeannette S
YR 2024
UL http://medrxiv.org/content/early/2024/09/06/2024.09.06.24313193.abstract
AB Background and aims Alcohol-associated hepatitis (AH) is the most life-threatening form of alcohol-associated liver disease (ALD). AH is characterized by severe inflammation attributed to increased levels of ethanol, microbes or microbial components, and damage-associated molecular pattern (DAMP) molecules in the liver. HSPB1 (Heat Shock Protein Family B (Small) Member 1; also known as Hsp25/27) is a DAMP that is rapidly increased in and released from cells experiencing stress, including hepatocytes. The goal of this study was to define the role of HSPB1 in AH pathophysiology.Methods Serum HSPB1 was measured in a retrospective study of 184 heathy controls (HC), heavy alcohol consumers (HA), patients with alcohol-associated cirrhosis (AC), and patients with AH recruited from major hospital centers. HSPB1 was also retrospectively evaluated in liver tissue from 10 HC and AH patients and an existing liver RNA-seq dataset. Finally, HSPB1 was investigated in a murine Lieber-DeCarli diet model of early ALD as well as cellular models of ethanol stress in hepatocytes and hepatocyte-macrophage communication during ethanol stress.Results Circulating HSPB1 was significantly increased in AH patients and levels positively correlated with disease-severity scores. Likewise, HSPB1 was increased in the liver of patients with severe AH and in the liver of ethanol-fed mice. In vitro, ethanol-stressed hepatocytes released HSPB1, which then triggered TNFα-mediated inflammation in macrophages. Anti-HSPB1 antibody prevented TNFα release from macrophages exposed to media conditioned by ethanol-stressed hepatocytes.Conclusions Our findings support investigation of HSPB1 as both a biomarker and therapeutic target in ALD. Furthermore, this work demonstrates that anti-HSPB1 antibody is a rational approach to targeting HSPB1 with the potential to block inflammation and protect hepatocytes, without inactivating host defense.HIGHLIGHTSHSPB1 is significantly increased in serum and liver of patients with alcohol-associated hepatitis.Ethanol consumption leads to early increases in HSPB1 in the mouse liver.Hepatocytes subjected to ethanol stress release HSPB1 into the extracellular environment where it activates TNFα-mediated inflammation in macrophages.Anti-HSPB1 antibody blocks hepatocyte-triggered TNFα in a model of hepatocyte-macrophage communication during ethanol stress.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NIDDK 1K08DK114713 (JSM), NIAAA Northeast Ohio Alcohol Research Center Pilot and Feasibility Award (JSM), NIAAA Northeast Ohio Alcohol Research Center 5P50AA024333 (LEN), NIAAA Johns Hopkins Clinical Resource for Alcoholic Hepatitis Investigation 5R24AA025017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocols were approved by the Institutional Review Boards (IRB) at the Cleveland Clinic and MetroHealth Hospitals. The IRB of Cleveland Clinic and MetroHealth Hospitals gave ethical approval for this work. All procedures were performed according to the IRB guidelines and all subjects provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.